Mucin quantity on MRI and outcomes following total neoadjuvant therapy in patients with rectal cancer
Sidra Javed-Tayyab(Memorial Sloan Kettering Cancer Center), Natally Horvat(Alliance Data (United States)), Canan Fırat(Memorial Sloan Kettering Cancer Center), Marinela Capanu(Memorial Sloan Kettering Cancer Center), Junting Zheng(Memorial Sloan Kettering Cancer Center), Thais Reif de Paula(Lankenau Medical Center), Rachel Nevin(Memorial Sloan Kettering Cancer Center), Marc J. Gollub(Memorial Sloan Kettering Cancer Center), Maria El Homsi(Memorial Sloan Kettering Cancer Center), Jinru Shia(Memorial Sloan Kettering Cancer Center), João Manoel Miranda Magalhães Santos(Universidade de São Paulo), Martin R. Weiser(Memorial Sloan Kettering Cancer Center), Lee Rodriguez(Memorial Sloan Kettering Cancer Center), Paulo Victor Alves Pinto(Universidade de São Paulo)
Cited by 2
Related Papers
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
|JAMA Oncology|2018|661
Practice Parameters for the Management of Rectal Cancer (Revised)
|Diseases of the Colon & Rectum|2013|565
Preoperative Treatment of Locally Advanced Rectal Cancer
|New England Journal of Medicine|2023|440
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
|Journal of Clinical Oncology|2009|390